Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: J Mol Med (Berl). 2019 May 17;97(7):1033–1047. doi: 10.1007/s00109-019-01791-z

Figure 1.

Figure 1.

A. Schematic representation of the AAV vector construct harboring the human cardiac S15D-RLC (huRLC-S15D-RLC) phosphomimic variant. Down panel: Fluorescence microscopy images of HEK293T cell culture transfected with pAAV-S15D-RLC-IRES-GFP (left-green fluorescence field; right-bright field). Scale bar is 0.1 mm. B. Overview of the AAV-gene therapy experiment: 5-7 mo-old WT and D166V HCM mice were injected with AAV9-S15D-RLC/PBS and were evaluated for the presence of virus via PCR and S15D-RLC protein via 2D-SDS-PAGE. 4-5 weeks post injection, the mice were evaluated for improvement of heart function by echocardiography (conventional and strain analysis), PV-loops, and contractile force measurement in skinned papillary muscles.